Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

Trial Details

NCT ID

NCT06005493

Phase

PHASE1 / PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

AZD5863

Locations (sample)

Jacksonville, Florida, United States|30.33218,-81.65565
Rochester, Minnesota, United States|44.02163,-92.4699
New York, New York, United States|40.71427,-74.00597
Beijing, China|39.9075,116.39723
Beijing, China|39.9075,116.39723

Key Eligibility Criteria

Age ≥ 18 at the time of signing the informed consent
Histologically confirmed diagnosis of adenocarcinoma of the stomach, gastro-esophageal junction, esophagus, or pancreas
Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Must show positive CLDN18.2 expression in tumor cells as determined by central immunohistochemistry (IHC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →